MERCURY LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 890 INR | -0.73% |
|
+1.14% | -13.56% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 468 | 406.8 | 337.2 | 771.1 | 582 | 702.5 |
| Enterprise Value (EV) 1 | 530.5 | 490.4 | 386.9 | 800.2 | 579.5 | 722.9 |
| P/E ratio | 23.2 x | 14.3 x | 10.4 x | 14.4 x | 15.8 x | 12.6 x |
| Yield | 0.38% | 0.44% | 0.71% | 0.54% | 0.72% | 0.6% |
| Capitalization / Revenue | 0.9 x | 0.73 x | 0.59 x | 1.12 x | 1 x | 0.93 x |
| EV / Revenue | 1.02 x | 0.88 x | 0.68 x | 1.17 x | 1 x | 0.96 x |
| EV / EBITDA | 12.3 x | 8.62 x | 6.32 x | 8.36 x | 8.63 x | 8.59 x |
| EV / FCF | -510 x | -17.1 x | 13.2 x | 57.9 x | 24.8 x | -22.6 x |
| FCF Yield | -0.2% | -5.84% | 7.57% | 1.73% | 4.04% | -4.42% |
| Price to Book | 1.78 x | 1.4 x | 1.05 x | 2.09 x | 1.44 x | 1.54 x |
| Nbr of stocks (in thousands) | 1,200 | 1,200 | 1,200 | 1,200 | 1,200 | 1,200 |
| Reference price 2 | 390.0 | 339.0 | 281.0 | 642.6 | 485.0 | 585.4 |
| Announcement Date | 9/17/18 | 9/4/19 | 9/2/20 | 9/1/21 | 9/1/22 | 9/1/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 518.7 | 555.2 | 572.7 | 686 | 579.2 | 753.3 |
| EBITDA 1 | 43.29 | 56.87 | 61.24 | 95.74 | 67.14 | 84.14 |
| EBIT 1 | 29.38 | 40.95 | 42.97 | 76.7 | 46.62 | 63.28 |
| Operating Margin | 5.67% | 7.38% | 7.5% | 11.18% | 8.05% | 8.4% |
| Earnings before Tax (EBT) 1 | 24.56 | 40.51 | 43.29 | 79.09 | 51.59 | 74.93 |
| Net income 1 | 20.13 | 28.36 | 32.28 | 53.37 | 36.86 | 55.79 |
| Net margin | 3.88% | 5.11% | 5.64% | 7.78% | 6.36% | 7.41% |
| EPS 2 | 16.78 | 23.63 | 26.90 | 44.48 | 30.72 | 46.49 |
| Free Cash Flow 1 | -1.041 | -28.62 | 29.28 | 13.81 | 23.41 | -31.94 |
| FCF margin | -0.2% | -5.15% | 5.11% | 2.01% | 4.04% | -4.24% |
| FCF Conversion (EBITDA) | - | - | 47.82% | 14.43% | 34.86% | - |
| FCF Conversion (Net income) | - | - | 90.7% | 25.88% | 63.49% | - |
| Dividend per Share 2 | 1.500 | 1.500 | 2.000 | 3.500 | 3.500 | 3.500 |
| Announcement Date | 9/17/18 | 9/4/19 | 9/2/20 | 9/1/21 | 9/1/22 | 9/1/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 62.5 | 83.6 | 49.7 | 29.2 | - | 20.4 |
| Net Cash position 1 | - | - | - | - | 2.49 | - |
| Leverage (Debt/EBITDA) | 1.443 x | 1.47 x | 0.8109 x | 0.3046 x | - | 0.2428 x |
| Free Cash Flow 1 | -1.04 | -28.6 | 29.3 | 13.8 | 23.4 | -31.9 |
| ROE (net income / shareholders' equity) | 7.92% | 10.3% | 10.6% | 15.5% | 9.55% | 13% |
| ROA (Net income/ Total Assets) | 3.57% | 4.7% | 4.73% | 7.88% | 4.53% | 6.08% |
| Assets 1 | 563.7 | 604 | 682.7 | 677.3 | 813.5 | 916.9 |
| Book Value Per Share 2 | 220.0 | 241.0 | 266.0 | 307.0 | 336.0 | 380.0 |
| Cash Flow per Share 2 | 22.10 | 2.380 | 10.80 | 25.30 | 34.30 | 30.90 |
| Capex 1 | 37.2 | 49.9 | 11.4 | 46.2 | 19.1 | 10.6 |
| Capex / Sales | 7.17% | 8.99% | 1.99% | 6.73% | 3.31% | 1.4% |
| Announcement Date | 9/17/18 | 9/4/19 | 9/2/20 | 9/1/21 | 9/1/22 | 9/1/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -13.56% | 12.93M | |
| +16.76% | 79.28B | |
| +7.97% | 8.74B | |
| -16.33% | 4.84B | |
| +51.22% | 4.74B | |
| +2.18% | 3.87B | |
| +20.93% | 2.46B | |
| -26.79% | 2.18B | |
| +15.12% | 2.09B | |
| -36.56% | 1.98B |
- Stock Market
- Equities
- MERCURYLAB6 Stock
- Financials Mercury Laboratories Limited
